Developing the Next Generation of Medicines for Human Diseases



Develop the next generation of novel therapeutics to address diseases caused by abnormal angiogenesis and infectious pathogens. Our proprietary molecules target simultaneously different human proteins implicated in abnormal vascular growth, cancer, tumor growth, ocular pathologies, and proteins from infectious pathogens including viruses and bacteria.

Novodux's platform consists of multi-targeted therapeutics comprising D-peptides with unique properties making them ideal drug candidates against several target areas including oncology, and infectious diseases.


Novodux aims to provide a novel class of therapeutics for several unmet medical needs and expects to provide a shareholder return based on outstanding performance.

Novodux's D-peptides directly impact on the cell by blocking the binding of proteins that are abnormally overexpressed or down regulated or mediated by infectious pathogens causing disease.

We are the only company with a platform of patented D-peptide based therapeutics.


The name Novodux is derived from Latin which means 'innovator' and ‘leader'.

These attributes reflect our leadership creating the next generation of innovative therapeutics.